This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders, Other  • Alert me on articles by topic

Arch Intern Med. 2003;163:1741.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Nateglinide, a rapidly acting insulinotrophic agent with a short duration of action, has been shown to selectively increase early insulin release in a glucose-sensitive manner. These properties have been demonstrated in vitro¹ and in vivo² in animals and in patients with type 2 diabetes mellitus.³ Nateglinide is indicated as monotherapy to lower the blood glucose levels in patients with type 2 diabetes whose hyperglycemia is not adequately controlled by diet and exercise alone and who have not been treated long-term with other antidiabetic agents.⁴

Report of a Case

A 34-year-old man was seen in the outpatient clinic for high blood glucose levels. His medical history revealed a diagnosis of type 2 diabetes mellitus 1 years ago. Treatment was initiated with glimepride, 2 mg/d, after the diagnosis. Eighteen months later, he was switched to nateglinide and metformin because his disease remained poorly controlled for the last 3 to 4 weeks. Two months later, however, the . . . [Full Text of this Article]

Comment
Correspondence to Alper Sevinc, MD, Gaziantep University School of Medicine, Department of Internal Medicine, Sahinbey Medical Center, Gaziantep, TR-27310 Turkey (e-mail: sevinc@gantep.edu.tr).